GlobeNewsWire
20 May 2026, 12:45 UTC · 1d ago
Source · https://www.globenewswire.com/news-release/2026/05/20/3298501/0/en/Propanc-Biopharma-s-CEO-Forecasts-New-Medical-Breakthroughs-in-the-Fight-Against-Pancreatic-Cancer-Over-the-Next-Decade.html
Read source
Search tags
Story key points
3 claims · impact-rated
Propanc Biopharma plans to file a Clinical Trial Application in Australia for a Phase 1b, First-In-Human study of its lead asset PRP in 30–40 advanced cancer patients later this year. — Transitioning from compassionate use to a formal First-In-Human clinical trial is a major valuation catalyst for a micro-cap biotech company.
+0.60Propanc's lead asset, PRP, has previously received US FDA Orphan Drug Designation for the treatment of pancreatic cancer. — Orphan designation provides regulatory incentives and market exclusivity, reducing the risk profile for development.
+0.30Propanc plans to conduct two Phase 2 studies involving 60 patients each for pancreatic and ovarian cancers following the completion of Phase 1. — Establishing a clear multi-indication roadmap for proof-of-concept increases the potential addressable market for the drug.
+0.20Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is announcing positive progress in its lead asset PRP and plans to file for a Phase 1b clinical trial.
Mentioned as having demonstrated significant advancements in the field of pancreatic cancer treatment.
Mentioned as having demonstrated significant advancements and improved survival rates in pancreatic cancer treatment.
